CTM inhibits cell proliferation and tumor growth specifically in TOV-112D and CAL33 cells carrying p53R175H with mRNA upregulation of p53 target genes, p21, PUMA, and MDM2, and increased DNA binding activity of p53R175H to p53-responsible elements in these genes. The gene discussed is TP53; the disease is neoplasm.